{"id":"fludrocortisone-fludrocortisone-acetate","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Fluid retention / edema"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Increased appetite"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":{"setId":"3c007f9a-4cd5-4e74-a633-d55dde1fe903","title":"FLUDROCORTISONE ACETATE TABLET [NCS HEALTHCARE OF KY, LLC DBA VANGARD LABS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fludrocortisone binds to mineralocorticoid receptors in the distal tubule and collecting duct of the nephron, promoting sodium retention and water reabsorption while enhancing potassium and hydrogen ion excretion. This leads to increased blood volume, elevated blood pressure, and correction of hyponatremia and hyperkalemia. It also possesses weak glucocorticoid activity, contributing to anti-inflammatory effects.","oneSentence":"Fludrocortisone is a synthetic corticosteroid that acts as a mineralocorticoid receptor agonist, increasing sodium reabsorption and potassium excretion in the kidneys to regulate fluid and electrolyte balance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:55:03.182Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adrenocortical insufficiency (Addison's disease)"},{"name":"Salt-wasting syndrome"},{"name":"Orthostatic hypotension"},{"name":"Hyponatremia"}]},"trialDetails":[{"nctId":"NCT06136650","phase":"PHASE3","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-18","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms","enrollment":1314},{"nctId":"NCT06353386","phase":"PHASE1, PHASE2","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-20","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":220},{"nctId":"NCT06136624","phase":"PHASE3","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Prostate Cancer Metastatic","enrollment":1310},{"nctId":"NCT06136598","phase":"PHASE1","title":"A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-30","conditions":"Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer","enrollment":14},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT06104449","phase":"PHASE1","title":"A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-14","conditions":"Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer","enrollment":6},{"nctId":"NCT07451886","phase":"PHASE2","title":"Adjunctive Fludrocortisone in Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-04-01","conditions":"Sepsis, Septic Shock, Sepsis - to Reduce Mortality in the Intensive Care Unit","enrollment":32},{"nctId":"NCT07383103","phase":"PHASE4","title":"Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock","status":"RECRUITING","sponsor":"Northern Jiangsu People's Hospital","startDate":"2026-03-02","conditions":"Septic Shock","enrollment":336},{"nctId":"NCT06860243","phase":"PHASE1","title":"A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Hepatic Impairment, Healthy Participants","enrollment":16},{"nctId":"NCT05440851","phase":"NA","title":"Platform of Randomized Adaptive Clinical Trials in Critical Illness","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-04-30","conditions":"Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High","enrollment":6250},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT06801236","phase":"PHASE1","title":"Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Acerand Therapeutics (Hong Kong) Limited","startDate":"2025-05-12","conditions":"Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)","enrollment":67},{"nctId":"NCT06609005","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Shenzhen Ionova Life Sciences Co., Ltd.","startDate":"2025-01-23","conditions":"Advanced Metastatic Castration Resistant Prostate Cancer","enrollment":84},{"nctId":"NCT06409364","phase":"PHASE2","title":"FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage","status":"RECRUITING","sponsor":"The George Institute","startDate":"2025-08-13","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":524},{"nctId":"NCT02574910","phase":"PHASE1","title":"Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-08-01","conditions":"Congenital Adrenal Hyperplasia","enrollment":4},{"nctId":"NCT06814132","phase":"PHASE1","title":"A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-07","conditions":"Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic","enrollment":24},{"nctId":"NCT04280497","phase":"NA","title":"Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-10","conditions":"Sepsis","enrollment":1800},{"nctId":"NCT06649409","phase":"PHASE1","title":"Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2024-06-05","conditions":"Pharmacodynamic","enrollment":30},{"nctId":"NCT03436485","phase":"PHASE1, PHASE2","title":"Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orion Corporation, Orion Pharma","startDate":"2018-03-19","conditions":"Prostate Cancer Metastatic","enrollment":204},{"nctId":"NCT07037043","phase":"PHASE3","title":"Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing for Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2025-08","conditions":"Inflammation in Cardiac Surgery","enrollment":196},{"nctId":"NCT00001521","phase":"PHASE3","title":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1995-06-08","conditions":"Congenital Adrenal Hyperplasia (CAH)","enrollment":66},{"nctId":"NCT07007910","phase":"PHASE1","title":"Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2024-12-18","conditions":"m CRPC","enrollment":90},{"nctId":"NCT06633419","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-18","conditions":"Healthy","enrollment":14},{"nctId":"NCT04404400","phase":"PHASE3","title":"Hydrocortisone and Fludrocortisone for Critical Illness-related Corticosteroid Insufficiency","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-02-17","conditions":"Critical Illness Related Corticosteroids Insufficiency","enrollment":1092},{"nctId":"NCT04552873","phase":"NA","title":"Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2020-12-03","conditions":"Hyponatremia, Subarachnoid Hemorrhage, SIADH","enrollment":52},{"nctId":"NCT05310253","phase":"NA","title":"Stress & Social Cognition in BPD (part 2)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2022-02-01","conditions":"Borderline Personality Disorder","enrollment":240},{"nctId":"NCT02919917","phase":"PHASE2, PHASE3","title":"Treatment of Post-SCI Hypotension","status":"COMPLETED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2017-06-01","conditions":"Spinal Cord Injury, Autonomic Dysreflexia, Orthostatic Hypotension","enrollment":66},{"nctId":"NCT06832566","phase":"PHASE4","title":"Ramadan Fasting Outcomes in Patients With Secondary Adrenal Insufficiency Before and After the Treatment of Hypotension.","status":"NOT_YET_RECRUITING","sponsor":"Hopital La Rabta","startDate":"2025-02-15","conditions":"Secondary Adrenal Insufficiency, Hypotension","enrollment":20},{"nctId":"NCT05555771","phase":"NA","title":"Paediatric Syncope in the Emergency Department","status":"RECRUITING","sponsor":"Dr. Victoria Claydon","startDate":"2022-09-03","conditions":"Syncope, Vasovagal, Postural Orthostatic Tachycardia Syndrome, Orthostatic Intolerance","enrollment":300},{"nctId":"NCT06566989","phase":"PHASE1","title":"A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-19","conditions":"Metastatic Prostate Cancer","enrollment":8},{"nctId":"NCT06554639","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-11","conditions":"Prostatic Neoplasms","enrollment":12},{"nctId":"NCT06513650","phase":"","title":"Mechanism-based Therapy of Hypotensive Syncope","status":"RECRUITING","sponsor":"Istituto Auxologico Italiano","startDate":"2024-05-01","conditions":"Syncope, Vasovagal, Neurally-Mediated","enrollment":140},{"nctId":"NCT05729724","phase":"","title":"Effect of Pharmacological Interventions on Systolic Blood Pressure Drops (SynABPM 2 Proof-of-concept)","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2022-10-05","conditions":"Syncope, Syncope, Vasovagal, Ambulatory Blood Pressure Monitoring","enrollment":111},{"nctId":"NCT04494789","phase":"PHASE2","title":"Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS","status":"COMPLETED","sponsor":"The George Institute","startDate":"2021-02-11","conditions":"Critically Ill, Septic Shock","enrollment":155},{"nctId":"NCT05001854","phase":"PHASE2, PHASE3","title":"Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline Septic Shock Patients","status":"SUSPENDED","sponsor":"Rennes University Hospital","startDate":"2022-03-31","conditions":"Septic Shock","enrollment":40},{"nctId":"NCT03773822","phase":"PHASE3","title":"Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.","status":"COMPLETED","sponsor":"CMC Ambroise Paré","startDate":"2019-04-19","conditions":"Cardiogenic Shock","enrollment":380},{"nctId":"NCT04128137","phase":"PHASE4","title":"Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension","status":"UNKNOWN","sponsor":"H.A.C. PHARMA","startDate":"2020-07-09","conditions":"Neurogenic Orthostatic Hypotension","enrollment":90},{"nctId":"NCT03548246","phase":"PHASE2","title":"Androgen Reduction in Congenital Adrenal Hyperplasia","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-01","conditions":"Congenital Adrenal Hyperplasia","enrollment":""},{"nctId":"NCT03550261","phase":"","title":"Salt Wasting, Hydro-sodium Balance and Fludrocortisone Requirement in Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-05-17","conditions":"Congenital Adrenal Hyperplasia (CAH)","enrollment":30},{"nctId":"NCT05453214","phase":"PHASE3","title":"Mineralocorticoid Use in COVID-19 Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-12-04","conditions":"COVID-19, ARDS","enrollment":10},{"nctId":"NCT01473108","phase":"PHASE1","title":"Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-03-29","conditions":"Clinical Pharmacology","enrollment":67},{"nctId":"NCT04952935","phase":"PHASE1, PHASE2","title":"Acupuncture for the Treatment of Medication-Dependent Hypotension in Heart Failure","status":"UNKNOWN","sponsor":"Scripps Health","startDate":"2021-04-20","conditions":"Congestive Heart Failure, Hypotension","enrollment":40},{"nctId":"NCT01030874","phase":"NA","title":"Orthostatic Hypotension Treatment on Rehab Unit","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2011-10","conditions":"Orthostatic Hypotension, Falls","enrollment":356},{"nctId":"NCT02871648","phase":"PHASE1","title":"The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-01","conditions":"Healthy Volunteers","enrollment":23},{"nctId":"NCT03710187","phase":"PHASE2","title":"HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients","status":"COMPLETED","sponsor":"University of Tennessee Medical Center","startDate":"2018-11-05","conditions":"Septic Shock","enrollment":84},{"nctId":"NCT04595942","phase":"PHASE3","title":"Midodrine and Fludrocortisone for Vasovagal Syncope","status":"UNKNOWN","sponsor":"Tehran Heart Center","startDate":"2020-11-19","conditions":"Syncope, Vasovagal","enrollment":1375},{"nctId":"NCT03001089","phase":"PHASE2","title":"Impact of the Administration of Fludrocortisone in Very Premature Infants","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-01","conditions":"Partial Mineralocorticoid Deficiency","enrollment":66},{"nctId":"NCT03500120","phase":"","title":"Diagnostic Accuracy of Seated Saline Suppression Test for Primary Aldosteronism","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2017-09-01","conditions":"Primary Aldosteronism","enrollment":200},{"nctId":"NCT01993680","phase":"PHASE2","title":"Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment","status":"COMPLETED","sponsor":"Christian Baumann","startDate":"2012-06","conditions":"Autonomic Disturbances in Parkinson's Disease","enrollment":18},{"nctId":"NCT04492280","phase":"PHASE4","title":"Evaluation of the Role of Hydrocortisone Either Alone or Combined With Fludrocortisone in the Outcome of Septic Shock in Adults","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-09-01","conditions":"Septic Shock","enrollment":66},{"nctId":"NCT03062150","phase":"NA","title":"Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2016-09-27","conditions":"Major Depression","enrollment":232},{"nctId":"NCT04351126","phase":"PHASE2","title":"Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response","status":"COMPLETED","sponsor":"Ganin Fertility Center","startDate":"2019-04-01","conditions":"Ovarian Hyperstimulation Syndrome","enrollment":107},{"nctId":"NCT01186185","phase":"EARLY_PHASE1","title":"Fludrocortisone for Sudden Hearing Loss","status":"TERMINATED","sponsor":"Oregon Health and Science University","startDate":"2012-08","conditions":"Hearing Loss, Sensorineural","enrollment":5},{"nctId":"NCT00118482","phase":"PHASE4","title":"Clinical Trial for the Prevention of Vasovagal Syncope","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2005-05","conditions":"Syncope, Vasovagal, Neurally-Mediated","enrollment":213},{"nctId":"NCT01690039","phase":"","title":"Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2012-09","conditions":"Acidosis, Renal Tubular, Nephrolithiasis, Vacuolar Proton-Translocating ATPases","enrollment":170},{"nctId":"NCT02140918","phase":"PHASE2","title":"Fludrocortisone in Healthy Volunteers (AFLUCO4)","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2014-07-01","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT01093261","phase":"PHASE3","title":"Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2010-08","conditions":"Traumatic Brain Injury, Trauma, Adrenal Insufficiency","enrollment":336},{"nctId":"NCT00625209","phase":"PHASE3","title":"Activated Protein C and Corticosteroids for Human Septic Shock","status":"COMPLETED","sponsor":"University of Versailles","startDate":"2008-03","conditions":"Septic Shock","enrollment":1241},{"nctId":"NCT00295347","phase":"NA","title":"Mineralocorticoid Receptor in the Treatment of Severe Depression","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2005-12","conditions":"Major Depression","enrollment":65},{"nctId":"NCT02532998","phase":"PHASE1","title":"A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09","conditions":"Pharmacodynamics, Healthy Subjects","enrollment":40},{"nctId":"NCT00117585","phase":"NA","title":"Orthostatic Hypotension in Rehabilitation Patients","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2005-11","conditions":"Hypotension, Orthostatic","enrollment":341},{"nctId":"NCT02478034","phase":"NA","title":"Effects of Mineralocorticoid Receptor Stimulation on Cognition","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2015-05","conditions":"Individuality","enrollment":80},{"nctId":"NCT00608101","phase":"NA","title":"Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Vanderbilt University","startDate":"2010-09","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT00623766","phase":"PHASE2","title":"Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-07","conditions":"Melanoma","enrollment":99},{"nctId":"NCT01648998","phase":"PHASE1","title":"Fludrocortisone and Information Processing in Healthy Volunteers","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2012-05","conditions":"Depression","enrollment":40},{"nctId":"NCT02069288","phase":"PHASE3","title":"Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"","conditions":"Septic Shock","enrollment":""},{"nctId":"NCT00673270","phase":"PHASE1, PHASE2","title":"Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression","status":"TERMINATED","sponsor":"Rennes University Hospital","startDate":"2008-05","conditions":"Renin Angiotensin","enrollment":13},{"nctId":"NCT00368381","phase":"PHASE4","title":"Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis","status":"WITHDRAWN","sponsor":"CAMC Health System","startDate":"2006-09","conditions":"Sepsis, Adrenal Insufficiency","enrollment":""},{"nctId":"NCT01453959","phase":"PHASE4","title":"Fludrocortisone's Test in Salt Sensitivity","status":"UNKNOWN","sponsor":"Fundação de Amparo à Pesquisa do Estado de São Paulo","startDate":"2011-07","conditions":"Hypertension","enrollment":40},{"nctId":"NCT00320099","phase":"PHASE3","title":"Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock","status":"COMPLETED","sponsor":"University of Versailles","startDate":"2006-01","conditions":"Septic Shock","enrollment":508},{"nctId":"NCT00103597","phase":"PHASE1","title":"Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy","status":"COMPLETED","sponsor":"Royal Brisbane and Women's Hospital","startDate":"2005-01","conditions":"Parkinson's Disease, Multiple System Atrophy, Orthostatic Hypotension","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":140,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fludrocortisone/ Fludrocortisone acetate","genericName":"Fludrocortisone/ Fludrocortisone acetate","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fludrocortisone is a synthetic corticosteroid that acts as a mineralocorticoid receptor agonist, increasing sodium reabsorption and potassium excretion in the kidneys to regulate fluid and electrolyte balance. Used for Adrenocortical insufficiency (Addison's disease), Salt-wasting syndrome, Orthostatic hypotension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}